Roche has added to its weight-loss drug pipeline again, turning to China's Rona Therapeutics for an RNAi candidate targeting ...

From patient engagement apps to clinical trial management platforms, development teams are increasingly turning to AI coding ...

Aspen Neuroscience, which is developing stem cell therapies for Parkinson's disease, has filed an IPO to raise additional ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Robbie Tyrie, founder and managing director of Torridon ...

Women and girls with autoimmune diseases are much more likely to have their condition misdiagnosed as psychiatric or ...

A phase 2/3 trial of BioNTech's immunotherapy for head and neck cancer, BNT113, has failed to meet its objective, but the ...

Saunders' latest spell as CEO started in 2023, as Bausch Health worked to spin Bausch + Lomb out as an independent public ...

Vinay Prasad has stepped down as head of the FDA's Center for Biologics Evaluation and Research (CBER), less than three months after taking on the role. His departure – first reported by STAT and now ...

Operational review meeting minutes released by the Department of Health and Social Care (DHSC) reveal that the industry and ...

Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards ...

Bristol Myers Squibb has reported phase 3 results with a new type of drug for idiopathic pulmonary fibrosis (IPF) that could ...

Expectations for Wnt pathway-targeting trispecific antibody remigromig (MK-3000, formerly known as EYE103) were riding high ...